Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 13, 2016 - Issue 6
Submit an article Journal homepage
296
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study

Damiano PaolicelliDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, ItalyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-8645-1763
ORCID Icon,
Eleonora CoccoMultiple Sclerosis Centre, Department of Public Health, Clinical Molecular Medicine, University of Cagliari, Cagliari, Italy
,
Valentina Di LecceDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy
,
Vita DirenzoDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy
,
Lucia MoiolaDepartment of Neurology, San Raffaele Scientific Institute, University of Milan, Milan, Italy
,
Roberta LanzilloDepartment of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University – School of Medicine, Naples, Italy
,
Paola PeriniMultiple Sclerosis Centre of the Veneto Region, Department of Neurosciences, University Hospital of Padua, Padua, Italy
,
Simona MalucchiNeurologia 2 – CRESM, A.O.U. San Luigi Gonzaga, Orbassano, Italy
,
Giovanna BorrielloMultiple Sclerosis Centre, Department of Neurology and Psychiatry, S. Andrea Hospital, Sapienza University, Rome, Italy
,
Emilio PortaccioDepartment of NEUROFARBA, University of Florence, Florence, Italy
,
Valentina PanettaL’altrastatistica srl – Consultancy & Training, Biostatistics office, Rome, Italy
,
Giuseppe FenuMultiple Sclerosis Centre, Department of Public Health, Clinical Molecular Medicine, University of Cagliari, Cagliari, Italy
,
Francesca SangalliDepartment of Neurology, San Raffaele Scientific Institute, University of Milan, Milan, Italy
,
Laura CacciaguerraMultiple Sclerosis Centre of the Veneto Region, Department of Neurosciences, University Hospital of Padua, Padua, Italy
,
Maria TrojanoDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, ItalyORCID Iconhttp://orcid.org/0000-0002-6329-8946
ORCID Icon & for the TRACER Group show all
Pages 799-805 | Received 07 Oct 2015, Accepted 22 Feb 2016, Published online: 12 Mar 2016

References

  • Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Eng J Med. 2000;343:938–2. doi:10.1056/NEJM200009283431307.
  • Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122:1180–1188. doi:10.1172/JCI58649.
  • Rudick RA. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. Arch Neurol. 1999;56:1079–1084. doi:10.1001/archneur.56.9.1079.
  • Murray TJ. The history of multiple sclerosis: the changing frame of the disease over the centuries. J Neurol Sci. 2009;277(Suppl 1):S3–S8. doi:10.1016/S0022-510X(09)70003-6.
  • Freedman MS. Disease-modifying drugs for multiple sclerosis: current and future aspects. Expert Opin Pharmacother. 2006;7(Suppl 1):S1–S9. doi:10.1517/14656566.7.1.S1.
  • Sabaté E. Adherence to long-term therapies: evidence for action. Geneva (Switzerland): World Health Organization; 2003.
  • Ivanova JI, Bergman RE, Birnbaum HG, et al. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. J Med Econ. 2012;15:601–609. doi:10.3111/13696998.2012.667027.
  • Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord. 2011;4:3–14. doi:10.1177/1756285610391693.
  • Devonshire V, Lapierre Y, Macdonell R, et al. The GAP study group. The global adherence project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:69–77. doi:10.1111/j.1468-1331.2010.03110.x.
  • Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256:568–576. doi:10.1007/s00415-009-0096-y.
  • Lugaresi A, Florio C, Brescia-Morra V, et al. Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicenter, open-label, phase IV study. BMC Neurol. 2012;12:7. doi:10.1186/1471-2377-12-7.
  • Willis H, Webster J, Larkin AM, et al. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart® injection device. Patient Prefer Adherence. 2014;8:843–851. doi:10.2147/PPA.S54986.
  • Bayas A, Ouallet JC, Kallmann B, et al. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin Drug Deliv. 2015;12:1239–1250. doi:10.1517/17425247.2015.1057567.
  • Moccia M, Palladino R, Russo C, et al. How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis. Expert Opin Drug Deliv. 2015;12(12):1829–1835. DOI:10.1517/17425247.2015.1078789.
  • Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302. doi:10.1002/ana.22366.
  • Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–286. doi:10.1212/WNL.0000000000000560.
  • Halpern R, Agarwal S, Dembek C, et al. Comparison of adherence and persistence among multiple sclerosis patients treated with disease modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence. 2011;5:73–84. doi:10.2147/PPA.S15702.
  • Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–574. doi:10.1002/pds.1230.
  • Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449–457.
  • Reynolds MW, Stephen R, Seaman C, et al. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin. 2010;26:663–674. doi:10.1185/03007990903554257.
  • Hupperts R, Becker V, Friedrich J, et al. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin Drug Deliv. 2015;12:15–25. doi:10.1517/17425247.2015.989209.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.